Dr Samuel Kemble PhD BSc

Dr Samuel Kemble

Institute of Inflammation and Ageing
Research Fellow

Contact details

Email
s.kemble@bham.ac.uk
Twitter
@Samuel1Kemble
View my research portal
Address
Institute of Inflammation and Ageing
Rheumatology Research Group
University of Birmingham Research Laboratories
Queen Elizabeth Hospital
Birmingham
B15 2WB

Dr Samuel Kemble is a postdoctoral research fellow with a keen interest in understanding how tissue resident cells govern the formation and persistence of specialised, pathological microenvironments in inflammatory disease.

A key focus of this research is to discover novel cell-specific proteins to employ and test advanced immunotherapies therapies (such as chimeric antigen receptor (CAR) T cells) to target pathogenic cell types and ultimately improve disease.

ORCID ID

Google Scholar 

ResearchGate

Qualifications

  • 2020 PhD, Institute of Inflammation and Ageing, University Birmingham
  • 2012 BSc Hons, Zoology, 2:1, Royal Holloway, University of London

Biography

Between 2014 and 2017, Dr Kemble was employed as a research technician within various institutes including the Mary Lyon’s Centre and the University of Birmingham working in the Dr. McGettrick, Prof. Buckley, and Prof. Andrew Filer research groups. During this time, Dr Kemble gained valuable expertise trialling therapeutic agents in experimental models of inflammatory disease.

Dr Kemble completed his PhD at the University of Birmingham in 2020 within the Dr. Harrison group, part of the Institute of Inflammation and Ageing and Birmingham platelet group where he pioneered the use of novel image-based flow cytometry techniques to characterise platelet formation in the blood.

In 2020, Dr Kemble moved to the Prof. Croft lab employed as a Post Doctoral Research Fellow. In his current role, Dr Kemble has gained vast experience in constructing single RNA sequencing libraries as well as using computational approaches to analyse these data sets. His role also includes cell specific functional validation and targeted approaches (using chimerical antigen receptor (CAR) T cells) to better understand the pathology of and treat inflammatory disease. respectively.

Publications

  1. Torres A, Kang S, Mahony CB, Cedeño M, Oliveira PG, Fernandez-Bustamante M, Kemble S, Laragione T, Gulko PS, Croft AP, Sanchez-Lopez E, Miyamoto S, Guma M. Role of mitochondria-bound HK2 in rheumatoid arthritis fibroblast-like synoviocytes. Front Immunol. 2023; 14: 1103231.
  2. Reyat JS, di Maio A, Grygielska B, Pike J, Kemble S, Rodriguez-Romero A, Karali CS, Croft AP, Psaila B, Simões F, Rayes J, Khan AO. Modelling the pathology and treatment of cardiac fibrosis in vascularised atrial and ventricular cardiac microtissues. Frontiers cardiovasc med (2023), 10: 1156759
  3. Ahmed S, Mahony CB, Torres A, Murillo-Saich J, Kemble S, Cedeno M, John P, Bhatti A, Croft AP, Guma M. Dual inhibition of glycolysis and glutaminolysis for synergistic therapy of rheumatoid arthritis. Arthritis Res Ther (2023), 25, (1), 176.
  4. Chidomere CI, Wahid M, Kemble S, Chadwick C, Thomas R, Hardy RS, McGettrick HM, Naylor AJ. Bench to Beside: Modelling Inflammatory Arthritis.Disc Imm (2023), 2, (1), Kyac010.
  5. Khan AO, Rodriguez-Romera A, Reyat JS, Olijnik A, Colombo M, Wang G, Wen GX, Murphy LC, Ling R, Elliott N, Sousos N, Kemble S, Grygielska B, Mahony CB, Stone AP, Croft AP, Bassett D, Poologasundarampillai G, Fielding AK, Cutler EA, Roy A, Gooding S, Rayes J, Machlus K, Psaila B. Human Bone Marrow Organoids for Disease Modelling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies. Cancer Dis (2023), 13 (2), 364-385.
  6. Korsunsky I, Wei K, Pohin M, Kim EY, Barone F, Major T, Taylor E, Ravindran R, Kemble S, Buckley CD, Brenner MD, Raychaudhuri S. Cross-tissue, single-cell stromal atlas identifies shared pathological fibroblast phenotypes in four chronic inflammatory diseases. Med (2022), 3 (7), 481-518,
  7. Kemble S, Dalby A, Lowe GC, Nicholson PLR, Watson SP, Senis Y, Thomas SG, Harrison P. Analysis of preplatelets and their barbell derivatives by imaging flow cytometry. Blood Adv (2022) 6 (9): 2932–2946.
  8. Kemble S and Croft AP. Critical Role of Synovial Tissue-Resident Macrophage and Fibroblast Subsets in the Persistence of Joint Inflammation. Front Immunol. (2021), 3;12:715894.
  9. Marsh LJ, Kemble S, Nisa PR, Singh R, Croft AP. Fibroblast pathology in inflammatory joint disease. Immunol Rev (2021), 302(1):163-183.
  10. Croft AP, Campos J, Jansen K, Turner J, Marshall J, Attar M, Savary L, Kemble S, Perlman H, Barone F, McGettrick HM, Fearon D, Wei K, Raychaudhuri S, Korsunsky I, Brenner MD, Coles M, Sansom S, Filer A, Buckley CD. Pathologically distinct fibroblast subsets drive inflammation and tissue damage in arthritis. Nature: 2019:570(7760):246-2
  11. Platelets 4thEd. (2019) Chapter 32 Platelet Counting. Kemble S, Briggs C, Harrison P, Elsevier.
  12. Filer A, Ward LSC, Kemble S, Davies CS, Munir H, Rogers R, Raza K, Buckley CD, Nash GB, McGettrick HM. Identification of a transitional fibroblast function in very early rheumatoid arthritis. Ann Rheum Dis (2017), 76(12):annrheumdis-2017-211286.
  13. Munir H, Ward LSC, Sheriff L, Kemble S, Nayar S, Barone F, Nash GB, McGettrick HM. Adipogenic differentiation of MSC alters their immunomodulatory properties in a tissue-specific manner, Stem Cells (2017), 35(6).

View all publications in research portal